Besides of the candidate biomarkers mentioned above, recent studies suggested that the methylation of the heparan sulfate 6-O-endosulfatase (SULF2) promoter was associated with sensitivity to Topo1 inhibitors in Non-Small-Cell Lung Cancer (NSCLC) [16]. This evidence concerns the gene SULF2 and non-small cell lung carcinoma.